Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Adocia

Next Previous
Drug Profile

Research programme: cancer therapeutics - Adocia

Alternative Names: Anticancer nanoparticles - Adocia; Cancer therapies - Adocia; DriveIn cancer therapeutics - Adocia; Ovarian cancer therapy - Adocia

Latest Information Update: 01 Aug 2016

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adocia
  • Class Proteins; Small molecules
  • Mechanism of Action DNA intercalators; Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Ovarian cancer; Solid tumours

Most Recent Events

  • 27 Jul 2016 Discontinued - Preclinical for Solid tumours and for Ovarian Cancer in France (Parenteral) before July 2016 - Adocia focusing on the development of treatment for diabetes only
  • 01 Nov 2014 Preclinical trials in Solid tumours and Ovarian cancer in France (Parenteral)
  • 09 Dec 2013 Adocia receives development and commercialisation rights to the DriveIn® nanotechnology from CNRS, University Bordeaux I and SATT Aquitaine in the field of healthcare

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top